Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 15/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21095154 | 1.00 | CYP2D6 (0.62) | CYP2D6HTR2AL3MBTL1ABCB1DRD2 | |
| SCHEMBL21095151 | 1.00 | CYP2D6 (0.62) | CYP2D6HTR2AL3MBTL1ABCB1DRD2 | |
| SCHEMBL21094969 | 0.94 | L3MBTL1 (0.66) | CYP2D6HTR2AL3MBTL1ABCB1DRD2 | |
| SCHEMBL21095145 | 0.94 | L3MBTL1 (0.66) | CYP2D6HTR2AL3MBTL1ABCB1DRD2 | |
| SCHEMBL21095146 | 0.94 | L3MBTL1 (0.66) | CYP2D6HTR2AL3MBTL1ABCB1DRD2 | |
| SCHEMBL23693979 | 0.89 | ABCB1 (0.56) | CYP2D6L3MBTL1ABCB1ADRB2ADRB1 | |
| SCHEMBL23693974 | 0.89 | ABCB1 (0.56) | CYP2D6L3MBTL1ABCB1ADRB2ADRB1 | |
| SCHEMBL23693975 | 0.89 | ABCB1 (0.56) | CYP2D6L3MBTL1ABCB1ADRB2ADRB1 | |
| SCHEMBL21792707 | 0.87 | ADRB2 (0.53) | L3MBTL1ABCB1ADRB2ADRB1ADRB3 | |
| SCHEMBL21095148 | 0.87 | CYP2D6 (0.67) | CYP2D6HTR2AABCB1DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | EXCIVA (UG) (haftungsbeschränkt) (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | CYP2D6 7/4885HTR2A 1705/4885L3MBTL1 4523/4885 |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP11B2, CYP2D6 | CYP2D6 3/4885HTR2A 2171/4885L3MBTL1 4471/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | CYP2D6 17/4885HTR2A 2/4885L3MBTL1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.